Trials / Completed
CompletedNCT00663884
Glufast On Insulin Glargine Trial in Type 2 DM
A Prospective, Randomized and Multi-center Clinical Study to Evaluate Efficacy and Safety of Combination Therapy of Mitiglinide or Voglibose With Long-acting Insulin in Type 2 Diabetic Patients
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 167 (actual)
- Sponsor
- JW Pharmaceutical · Industry
- Sex
- All
- Age
- 30 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
We will evaluate the efficacy and safety of combination therapy of 10 mg mitiglinide or 0.2mg voglibose with insulin glargine for 16 weeks after single administration of insulin glargine for 4 weeks in type 2 diabetic patients whose glycemic control were not enough despite administration of oral antidiabetic drug or insulin glargine.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Mitiglinide | mitiglinide 10mg three times a day before a meal |
| DRUG | Voglibose | voglibose 0.2mg three times a day before a meal |
Timeline
- Start date
- 2008-02-01
- Primary completion
- 2009-07-01
- Completion
- 2009-09-01
- First posted
- 2008-04-22
- Last updated
- 2012-03-30
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT00663884. Inclusion in this directory is not an endorsement.